Salivary Cotinine ELISA Kit (DEIA066129)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
saliva
Species Reactivity
Human
Intended Use
The CD cotinine kit is a competitive immunoassay designed and validated for the quantitative measurement of cotinine in saliva samples. This kit may be used to measure primary or secondhand exposure to nicotine. This kit is not for use in diagnostic procedures. It is intended only for research use in humans and some animals. A validated urine protocol is available on request.
Please read the complete kit insert before performing this assay. Failure to follow kit procedure and recommendations for saliva collection and sample handling may result in false values. For further information about this kit, its application, or the procedures in this insert, please contact the technical service team at CD or your local sales representative.
Contents of Kit
1. Microtitre Plate 1/96-well
2. Antiserum Contains: rabbit anti-cotinine antibody, buffer, preservative. 1 bottle/15 mL
3. Cotinine Standard In a saliva-like matrix. Contains: cotinine, buffer, preservative. 1 vial/500 µL
4. Cotinine Controls High, Low, in a saliva-like matrix. Ready to use. Contain: cotinine, buffer, preservative. 2 vials/250 µL each
5. Wash Buffer Concentrate (10X) Contains: phosphate buffer, detergent, preservative. 1 bottle/100 mL
6. Assay Diluent Contains: phosphate buffer, pH indicator, preservative. 1 bottle/60 mL
7. Cotinine Enzyme Conjugate Concentrate. Dilute before use with assay diluent. (See step 5 of procedure.) Contains: Cotinine conjugated to HRP, preservative. 1 vial/75 µL
8. TMB Substrate Solution Non-toxic, ready to use. 1 bottle/ 25 mL
9. 2 M Stop Solution Contains: sulfuric acid. 1 bottle/12.5 mL
Storage
All components of this kit are stable at 2-8°C until the kit's expiration date.
Precision
Intra-assay Precision (n=10): 4.5%-8.6%
Inter-assay Precision (n=8): 4.2%-9.0%
Sensitivity
The lower limit of sensitivity was determined by interpolating the mean optical density minus 2 SDs of 10 sets of duplicates at the 0 ng/mL level. The minimal concentration of cotinine that can be distinguished from zero is 0.15 ng/mL.
General Description
The detection of exposure to tobacco smoke by measurement of cotinine is the preferred method. Nicotine is not considered a valid marker of smoking status due to its relatively short half-life (approximately 2 hours). By contrast, cotinine has an average half-life of 17 hours, and blood levels closely reflect the dose of nicotine absorbed from tobacco smoke. Saliva samples are easier to obtain, however, and saliva levels are highly correlated and used interchangeably with blood levels.
There is a clear need for inexpensive, accurate, quantitative, and noninvasive means of validating smoking status, measuring the immediate physiological consequences of individual differences and intraindividual change in smoking behaviors, and determining secondhand tobacco smoke exposure. CD has designed this research tool to provide biomedical researchers with a highly sensitive and reliable means to do so.
Cotinine levels in biologic fluids have been measured by chromatographic (GC or HPLC – sometimes coupled with mass spectrometry) and immunoassay methods. Chromatographic methods have the advantage of higher specificity and sensitivity, but EIA cotinine results have shown near perfect agreement with GC/MS confirmation of smoking status. Immunoassay methods also use smaller sample volumes than chromatography methods and they do not require extractions or other manipulations of the samples, making them easier to use in large-scale epidemiological studies and avoiding the need for specialized laboratories. Levels, however, may be higher with EIA since metabolites of cotinine, such as 3-OH-cotinine, are also measured.
Standard Curve

Citations


Have you cited DEIA066129 in a publication? Let us know and earn a reward for your research.

Related Products


Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Association of Self-Reported and Cotinine-Verified Smoking Status with Atrial Arrhythmia

JOURNAL OF KOREAN MEDICAL SCIENCE

Authors: Lee, Sung Ho; Kim, Byung Jin; Kang, Jeonggyu; Seo, Dae Chul; Lee, Seung Jae

Background: The relationship between self-reported and urinary cotinine-verified smoking status and atrial arrhythmia (AA) is unclear. The aim of this study was to evaluate the association of self-reported and urine cotinine-verified smoking status with AA. Method: A total of 201,788 participants (106,375 men, mean age 37 years) who had both a urinary cotinine measurement and electrocardiogram were included. Cotinine-verified current smoking was defined as a urinary cotinine level above 50 ng/mL. Individuals were divided into three groups based on self-reported smoking and two groups based on cotinineverified smoking status. Results: Among overall subjects, 505 had documented AA (0.3%) and 135 had atrial fibrillation (AF) (0.1%). Self-reported current smoking was associated with an increased risk of AA (odds ratio [OR], 1.42; 95% confidence interval [CI], 1.06-1.91; P = 0.019) and AF (OR, 2.20; 95% CI, 1.24-3.90; P = 0.007), whereas self-reported former smoking had no significant association with AA (OR, 1.30; 95% CI, 0.97-1.73; P = 0.078) and AF (OR, 1.74; 95% CI, 1.00-3.04; P = 0.051). Cotinine-verified current smoking showed no significant association with AA (OR, 1.24; 95% CI, 0.98-1.58; P = 0.080) and AF (OR, 1.20; 95% CI, 0.79-1.83; P = 0.391). Conclusion: Self-reported current smoking was associated with AA and AF, while self reported former smoking and cotinine-verified current smoking showed no significant association with AA and AF.

Feasibility of Collecting Saliva for Biological Verification of Tobacco Use Status in Dental Practices and Patients' Homes: Results from the National Dental PBRN

COMMUNITY DENTAL HEALTH

Authors: Stoops, William W.; Johnson, Meghan F.; Strickland, Justin C.; Knudsen, Hannah K.; Gilbert, Gregg H.; Massingale, Shermetria D.; Ray, Midge N.; Studts, Christina R.; Atchley, Lana; Reynolds, George; Slade, Emily; Studts, Jamie L.

Objective: To evaluate the feasibility of collecting and analyzing saliva samples from dental practices and patients' homes for biochemical verification of tobacco use status. Basic research design: Sub-study within single-arm, multi-center, longitudinal clinical study. Clinical setting: Dental practices in the South Central region of the United States National Dental Practice-Based Research Network and patients' homes. Participants: Fifty-five patients recruited from 30 dental practices. Interventions: Participants in the sub-study were instructed on saliva collection for cotinine analysis in dental practices where they enrolled in the primary study. Saliva was collected at the practices and then from patients' homes. Main outcome measures: Feasibility for dental practice collection was define as 80% of enrolled participants having analyzable samples. For patients' home collection, feasibility was defined as 70%. Results: Forty-seven samples (i.e., 86% of those enrolled) collected in dental practices were analyzable. Twenty-one samples (i.e. 38% of those enrolled) collected in patients' homes were analyzable. Conclusions: Collecting saliva samples for cotinine analysis from dental practices, but not from patients' homes, was feasible. Dental practices may provide an advantageous setting for biochemically verifying tobacco use status as part of clinical trials for tobacco cessation.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket